Activity Description

In 15 minutes, you can watch this on-demand, case discussion about DL from the proceedings of a Women’s Health Issues CE course held on April 30, 2016, in Pasadena, California. Learn about:

• The safety and efficacy of available pharmacotherapies to treat genitourinary syndrome of menopause (GSM)
• How to initiate conversations about GSM with your menopausal and postmenopausal patients
• Interpreting the NAMS position statement recommendations to diagnose and manage your menopausal and postmenopausal patients with GSM

Learning Objectives

Upon completion of this activity, learners should be able to:

• Interpret the North American Menopause Society (NAMS) position statement recommendations to diagnose and manage menopausal and postmenopausal women for GSM 
• Review the safety and efficacy of currently available pharmacotherapies for GSM 
• Utilize communication strategies to initiate conversations regarding GSM with menopausal and postmenopausal patients

Faculty

Faculty Biography

Susan E. Hoffstetter, PhD, WHNP-BC, FAANP 

Susan Hoffstetter, PhD, WHNP-BC, FAANP, is an Associate Professor in the Department of Obstetrics, Gynecology, and Women’s Health at Saint Louis University School of Medicine in Missouri. Dr Hoffstetter completed her BSN degree and MSN women’s health nurse practitioner degree from the University of Missouri-St. Louis. She went on to receive her PhD in higher education from Saint Louis University. 

In her clinical practice, Dr Hoffstetter specializes in vulvovaginal disease and urogynecology. She also instructs and supervises resident physicians and medical students, and serves as a preceptor for nurse practitioner students. Her clinical research interest is vulvovaginal disease, for which she has been involved in numerous clinical trials. Dr Hoffstetter is the author or co-author of various journal articles, book chapters, and teaching guides. She has lectured extensively nationally and internationally on topics affecting women’s health including vaginal and vulvar disease, menopause, urinary incontinence, overactive bladder, interstitial cystitis, osteoporosis, and domestic violence. Dr Hoffstetter maintains memberships in several professional organizations. She serves as immediate past Chair of the board of directors for the National Association of Nurse Practitioners in Women’s Health, and is a Fellow in both the International Society for the Study of Vulvovaginal Disease and the American Academy of Nurse Practitioners. Dr Hoffstetter is the recipient of several awards including the STAR Award for work in domestic violence education, and in 2015, she was named one of the 20 Outstanding Professors of Women’s Health Nursing by the Nurse Practitioner Schools.

Disclosure Statements

Nurse Practitioners in Women’s Health (NPWH) policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity.  

Conflicts of interest were resolved according to NPWH policy prior to development of content. 

NPWH policy requires authors to disclose to the participant when presenting information about unlabeled use of any commercial product or device or an investigational use of a drug or device not yet approved for any use. 

Faculty

Susan E. Hoffstetter, PhD, WHNP-BC, FAANP

Susan E. Hoffstetter has indicated that she has no disclosures to be made.

Educational Planning Committee

Spire Learning

Jaime Symowicz, PhD, Lauren Waters, and Lisa Conklin have nothing to disclose.

National Association of Nurse Practitioners in Women’s Health

Gay Johnson and Susan Rawlins, MS, WHNP-BC, NP, have nothing to disclose. 

Disclaimer

The participating faculty determines the editorial content of the CE activity and the content does not necessarily represent the views of NPWH or Spire Learning. This content has been peer reviewed for validation of clinical content. While every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with those of established recommendations of other authorities, national guidelines, FDA-approved package inserts, and individual patient characteristics. 

Off-label Statement 

This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Levels of Evidence 

The following levels of evidence are provided for any patient care recommendations made in this presentation and are denoted by a superscript A, B, or C. 

Strength of Recommendation

• Level A: supported by sufficient, consistent scientific evidence (eg, multiple, randomized clinical trials or meta-analyses)
• Level B: supported by limited or inconsistent evidence (eg, nonrandomized trials or single randomized trial)
• Level C: based primarily on expert opinion